Two Sigma Advisers’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.02M | Buy |
+2,334,900
| New | +$4.02M | 0.01% | 814 |
|
|
2023
Q3 | – | Sell |
-802,700
| Closed | -$5.65M | – | 2478 |
|
|
2023
Q2 | $5.65M | Sell |
802,700
-441,500
| -35% | -$3.11M | 0.01% | 710 |
|
|
2023
Q1 | $7.6M | Buy |
1,244,200
+396,800
| +47% | +$2.42M | 0.02% | 644 |
|
|
2022
Q4 | $5.41M | Buy |
847,400
+172,700
| +26% | +$1.1M | 0.02% | 752 |
|
|
2022
Q3 | $6.46M | Buy |
674,700
+491,600
| +268% | +$4.71M | 0.02% | 635 |
|
|
2022
Q2 | $2.02M | Buy |
183,100
+132,400
| +261% | +$1.46M | 0.01% | 1210 |
|
|
2022
Q1 | $844K | Buy |
50,700
+4,500
| +10% | +$74.9K | ﹤0.01% | 1727 |
|
|
2021
Q4 | $882K | Buy |
+46,200
| New | +$882K | ﹤0.01% | 1623 |
|
|
2021
Q2 | – | Sell |
-103,200
| Closed | -$3.27M | – | 2560 |
|
|
2021
Q1 | $3.27M | Sell |
103,200
-20,900
| -17% | -$662K | 0.01% | 1043 |
|
|
2020
Q4 | $5.76M | Buy |
124,100
+78,900
| +175% | +$3.66M | 0.02% | 766 |
|
|
2020
Q3 | $1.49M | Buy |
45,200
+7,500
| +20% | +$247K | ﹤0.01% | 1313 |
|
|
2020
Q2 | $1.04M | Sell |
37,700
-1,200
| -3% | -$32.9K | ﹤0.01% | 1563 |
|
|
2020
Q1 | $1.16M | Sell |
38,900
-61,900
| -61% | -$1.85M | ﹤0.01% | 1389 |
|
|
2019
Q4 | $2.79M | Buy |
100,800
+73,300
| +267% | +$2.03M | 0.01% | 1074 |
|
|
2019
Q3 | $501K | Buy |
+27,500
| New | +$501K | ﹤0.01% | 1710 |
|
|
2019
Q2 | – | Sell |
-51,400
| Closed | -$489K | – | 2373 |
|
|
2019
Q1 | $489K | Sell |
51,400
-36,600
| -42% | -$348K | ﹤0.01% | 1806 |
|
|
2018
Q4 | $779K | Buy |
+88,000
| New | +$779K | ﹤0.01% | 1594 |
|
|
2018
Q3 | – | Sell |
-19,800
| Closed | -$253K | – | 2305 |
|
|
2018
Q2 | $253K | Buy |
+19,800
| New | +$253K | ﹤0.01% | 2147 |
|